Company Overview and News
Next Saturday is not only The Everest, Australia's richest horse race and the highlight of the Sydney Spring racing carnival, but also Olympic champion Ian Thorpe’s 36th birthday. The swimmer formerly known as the Thorpedo will join model Jennifer Hawkins and radio host Emma Freedman, his fellow Star ambassadors, trackside at Randwick next week to cheer on The Star's entry in the race, Shoals.
Michael Kors Holdings Limited (KORS - Free Report) is in the process of becoming a multi-brand destination and looking to create a niche in the luxury fashion space. Notably, the recent agreement to buy iconic Italian fashion brand, Versace, for an enterprise value of approximately $2.12 billion is another step toward the same. Last year, the branded fashion company successfully acquired the luxury-footwear brand, Jimmy Choo.
CHOO KORS ZUMZ URBN JYMHF BOOT
Michael Kors (KORS) has closed a deal to buy Versace for $2.12 billion. Initial news of the potential acquisition resulted in a sell-off in Kors stock, causing the stock price to drop 8.21%.
CHOO TPR MC JYMHF
Say goodbye to Michael Kors (NYSE:KORS), the iconic fashion brand that has cycled in and out of popularity over the past several years. And say hello to Capri Holdings (NYSE:CPRI), the global high-end fashion conglomerate that will soon include Michael Kors, Versace, and Jimmy Choo.
CHOO KORS JYMHF
This undated photo provided by Michael Kors shows from left, CEO of Versace Jonathan Akeroyd, Donatella Versace, and chairman and CEO of Michael Kors John D. Idol. Image: Rahi Rezvani/Michael Kors Holdings Ltd. via AP
CHOO KORS KATE JYMHF
Michael Kors is buying the Italian fashion house Versace in a deal worth more than US$2 billion (NZ$3 billion), continuing its hard charge into the world of high-end fashion.
CHOO KORS KATE JYMHF
Michael Kors Holdings Ltd. (NYSE: KORS) announced early on Tuesday that it would be acquiring the Italian luxury fashion house Gianni Versace and adding it to its portfolio. The combined company will be changing its name following the acquisition.
CHOO KORS DTK JYMHF
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to LSE:CHOO / JIMMY CHOO PLC on message board site Silicon Investor.